Dr. Reddy's Laboratories Launches Generic Version of Ciprodex Otic Suspension, USP in the US Market
12 August 2020 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the US Food and Drug Administration (USFDA), the company said.

The Ciprodex brand had US sales of approximately USD 453m MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.

Dr. Reddy's Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, is available as 7.5 mL fill in a 10 mL bottle.

Dr. Reddy's Laboratories is an integrated pharmaceutical company. Through its three businesses Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. its major markets include USA, India, Russia and CIS countries, and Europe.